Pre-Clinical Study:
Viaskin^™ Egg

DBV is exploring Viaskin Egg for the treatment of hen’s egg allergy.

Hen’s egg allergy is one of the most common food allergies in children. Several global studies suggest that egg allergy affects 1.5 – 3 percent of young children.

DBV began pre-clinical work for Viaskin Egg in 2015, with the goal of initiating a clinical program if these studies are successful. Preclinical development is currently ongoing.

*Viaskin™ Egg is a product under pre-clinical development and has not been approved for any use in any country, including, but not limited to, the United States, Canada, the European Union or Australia.